STAA - STAAR Surgical Co Stock Price, Fair Value and News

47.82USD-0.37 (-0.77%)Market Closed

Market Summary

USD47.82-0.37

Market Closed

-0.77%

STAA Stock Price

View Fullscreen

STAA RSI Chart

STAA Valuation

Market Cap

2.4B

Price/Earnings (Trailing)

110.31

Price/Sales (Trailing)

7.3

EV/EBITDA

55.96

Price/Free Cashflow

-655.22

STAA Price/Sales (Trailing)

STAA Profitability

EBT Margin

10.45%

Return on Equity

5.53%

Return on Assets

4.37%

Free Cashflow Yield

-0.15%

STAA Fundamentals

STAA Revenue

Revenue (TTM)

322.4M

Rev. Growth (Yr)

19.09%

Rev. Growth (Qtr)

-5.02%

STAA Earnings

Earnings (TTM)

21.3M

Earnings Growth (Yr)

14.68%

Earnings Growth (Qtr)

61.01%

Breaking Down STAA Revenue

Last 7 days

3.5%

Last 30 days

30.6%

Last 90 days

60.8%

Trailing 12 Months

-32.0%

How does STAA drawdown profile look like?

STAA Financial Health

Current Ratio

5.62

STAA Investor Care

Shares Dilution (1Y)

1.31%

Diluted EPS (TTM)

0.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	294.7M	305.9M	310.2M	322.4M
2022	242.9M	261.7M	279.3M	284.4M
2021	179.0M	206.2M	217.5M	230.5M
2020	152.8M	148.3M	156.3M	163.5M
2019	129.4M	135.2M	142.5M	150.2M
2018	97.4M	109.3M	117.6M	124.0M
2017	83.5M	84.5M	87.9M	90.6M
2016	77.5M	79.9M	81.2M	82.4M
2015	73.7M	72.3M	72.8M	77.1M
2014	74.4M	76.3M	77.4M	75.0M
2013	66.3M	68.5M	69.7M	72.2M
2012	63.4M	63.1M	63.7M	63.8M
2011	56.0M	58.7M	60.8M	62.8M
2010	0	52.4M	53.7M	55.0M
2009	0	0	0	51.1M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of STAAR Surgical Co

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 14, 2024	weisner aimee s	bought	66,692	38.11	1,750	-
Mar 12, 2024	butcher arthur c	acquired	-	-	649	-
Mar 12, 2024	jiang wei	acquired	-	-	1,299	-
Mar 07, 2024	williams patrick f.	acquired	-	-	2,614	chief financial officer
Jan 08, 2024	broadwood partners, l.p.	bought	-	-	-	-
Jan 08, 2024	broadwood partners, l.p.	bought	109,570	27.1079	4,042	-
Jan 05, 2024	broadwood partners, l.p.	bought	4,463,230	28.4765	156,734	-
Jan 05, 2024	broadwood partners, l.p.	bought	-	-	-	-
Jan 04, 2024	broadwood partners, l.p.	bought	-	-	-	-
Jan 04, 2024	broadwood partners, l.p.	bought	1,828,180	28.9059	63,246	-

Which funds bought or sold STAA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Louisiana State Employees Retirement System	reduced	-0.82	164,852	926,376	0.02%
Apr 23, 2024	RICE HALL JAMES & ASSOCIATES, LLC	reduced	-0.01	350,331	1,897,350	0.11%
Apr 23, 2024	FIFTH THIRD BANCORP	added	1,533	8,911	9,379	-%
Apr 23, 2024	PFG Private Wealth Management, LLC	unchanged	-	50.00	268	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	58.00	268	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-28.5	-82,000	579,000	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	unchanged	-	86,515	468,432	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-231,426	805,218	0.01%
Apr 19, 2024	Maryland State Retirement & Pension System	reduced	-1.56	264,171	821,706	0.02%
Apr 19, 2024	State of Alaska, Department of Revenue	reduced	-1.00	201,000	1,138,000	0.01%

Are Funds Buying or Selling STAA?

Are funds buying STAA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own STAA

No. of Funds

Unveiling STAAR Surgical Co's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	11.20%	5,468,710	SC 13G/A
Jan 26, 2024	baillie gifford & co	9.11%	4,448,208	SC 13G/A
Jan 22, 2024	blackrock inc.	16.7%	8,159,763	SC 13G/A
Jan 10, 2024	broadwood partners, l.p.	22.1%	0	SC 13D/A
Nov 15, 2023	broadwood partners, l.p.	20.7%	0	SC 13D/A
Oct 10, 2023	broadwood partners, l.p.	19.5%	0	SC 13D/A
Sep 07, 2023	blackrock inc.	17.2%	8,328,302	SC 13G/A
Feb 09, 2023	vanguard group inc	11.01%	5,306,915	SC 13G/A
Jan 23, 2023	blackrock inc.	11.9%	5,738,044	SC 13G/A
Jan 19, 2023	baillie gifford & co	10.87%	5,240,456	SC 13G/A

Recent SEC filings of STAAR Surgical Co

View All Filings

Date Filed	Form Type	Document
Apr 04, 2024	8-K	Current Report
Mar 18, 2024	8-K	Current Report
Mar 15, 2024	UPLOAD	UPLOAD
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading

Peers (Alternatives to STAAR Surgical Co)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-2.69%	-2.54%	32.41	4.63	-8.12%	-17.45%
BDX	67.5B	19.5B	-4.86%	-10.59%	53.77	3.46	4.02%	-22.04%
ALGN	23.6B	3.9B	-2.36%	-14.10%	52.95	6.1	3.42%	23.09%
BAX	20.8B	14.8B	-2.22%	-9.67%	7.83	1.4	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	-0.49%	-14.47%	22.62	0.76	-2.44%	-22.68%
ATR	9.3B	3.5B	-1.02%	16.40%	32.52	2.65	4.97%	18.89%
BIO	8.1B	2.7B	-18.63%	-38.25%	-12.74	3.04	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.77%	-25.53%	-47.67	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-2.62%	10.65%	-558.61	9.25	33.86%	89.83%
PDCO	2.3B	6.6B	-4.73%	-4.84%	12.02	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-11.22%	-19.13%	-1.92	0.41	7.73%	-1066.14%
ANIK	383.0M	166.7M	1.30%	-3.37%	-4.63	2.3	6.67%	-456.34%
ANGO	241.5M	324.0M	12.50%	-31.24%	-1.26	0.75	-3.19%	-337.41%
APYX	45.7M	52.3M	5.60%	-56.15%	-2.44	0.87	17.61%	19.28%
AEMD	4.0M	3.7M	-11.70%	184.91%	-0.32	1.06	5.77%	8.23%

STAAR Surgical Co News

Latest updates

STAAR Surgical Co Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-5.0%	76.00	80.00	92.00	74.00	64.00	76.00	81.00	63.00	59.00	58.00	62.00	51.00	46.00	47.00	35.00	35.00	39.00	39.00	40.00	33.00	31.00
Gross Profit	-4.6%	61.00	64.00	71.00	58.00	50.00	60.00	64.00	49.00	45.00	45.00	49.00	39.00	34.00	35.00	24.00	25.00	29.00	29.00	30.00	24.00	23.00
S&GA Expenses	-12.2%	50.00	57.00	62.00	55.00	49.00	47.00	47.00	37.00	38.00	37.00	39.00	32.00	30.00	30.00	25.00	26.00	26.00	26.00	25.00	23.00	22.00
R&D Expenses	-5.3%	11.00	11.00	12.00	10.00	10.00	10.00	9.00	8.00	9.00	8.00	8.00	8.00	9.00	9.00	7.00	7.00	7.00	6.00	6.00	6.00	6.00
EBITDA Margin	20.2%	0.12*	0.10*	0.12*	0.15*	0.18*	0.18*	0.17*	0.17*	0.15*	0.15*	0.15*	0.11*	-	-	-	-	-	-	-	-	-
Income Taxes	210.2%	6.00	2.00	2.00	2.00	-0.78	2.00	2.00	2.00	-0.96	1.00	2.00	1.00	1.00	1.00	1.00	-1.16	-3.40	1.00	1.00	0.00	0.00
Earnings Before Taxes	103.7%	14.00	7.00	8.00	5.00	6.00	13.00	15.00	12.00	7.00	7.00	11.00	6.00	5.00	5.00	-0.62	-1.29	3.00	3.00	5.00	2.00	1.00
EBT Margin	25.0%	0.10*	0.08*	0.10*	0.13*	0.16*	0.17*	0.16*	0.15*	0.14*	0.13*	0.13*	0.09*	-	-	-	-	-	-	-	-	-
Net Income	61.0%	8.00	5.00	6.00	3.00	7.00	10.00	13.00	10.00	5.00	6.00	9.00	5.00	3.00	4.00	-1.17	-0.13	6.00	2.00	4.00	1.00	1.00
Net Income Margin	0.9%	0.07*	0.07*	0.08*	0.11*	0.14*	0.14*	0.13*	0.12*	0.11*	0.11*	0.10*	0.06*	-	-	-	-	-	-	-	-	-
Free Cashflow	290.5%	29.00	-15.16	-9.32	-7.99	-1.05	18.00	8.00	-7.15	4.00	19.00	3.00	5.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	3.6%	489	472	441	419	419	395	376	351	346	325	294	266	257	235	218	207	208	193	186	177	167
Current Assets	5.2%	365	347	328	313	312	297	296	274	271	264	248	224	216	196	183	172	175	165	159	153	152
Cash Equivalents	43.6%	183	127	95.00	90.00	86.00	129	202	193	200	196	173	162	152	128	116	111	120	112	103	102	104
Net PPE	6.3%	67.00	63.00	56.00	53.00	51.00	48.00	43.00	40.00	36.00	32.00	29.00	26.00	24.00	23.00	21.00	20.00	17.00	15.00	13.00	11.00	11.00
Goodwill	0%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Liabilities	10.6%	103	93.00	87.00	80.00	83.00	75.00	77.00	75.00	87.00	75.00	60.00	52.00	60.00	48.00	43.00	42.00	48.00	43.00	42.00	40.00	35.00
Current Liabilities	14.6%	65.00	57.00	54.00	47.00	52.00	45.00	47.00	41.00	49.00	47.00	42.00	36.00	41.00	34.00	32.00	30.00	34.00	30.00	29.00	28.00	28.00
Shareholder's Equity	1.9%	386	379	358	339	336	323	302	276	262	249	235	214	197	186	175	165	160	149	144	137	132
Retained Earnings	14.1%	-47.37	-55.12	-63.86	-69.92	-68.71	-78.49	-88.75	-101	-108	-116	-122	-130	-135	-139	-143	-141	-141	-148	-150	-154	-156
Additional Paid-In Capital	0.2%	437	436	420	409	404	398	387	379	374	369	360	348	338	328	320	309	304	300	296	293	290
Shares Outstanding	0.0%	49.00	49.00	48.00	48.00	48.00	48.00	48.00	48.00	47.00	47.00	47.00	47.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	2,567	-	-	-	3,467	-	-	-	6,859	-	-	-	2,821	-	-	-	1,308	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	635.0%	31,969	-5,975	-6,306	-5,094	2,970	24,109	13,246	-4,610	8,498	22,316	6,382	6,766	19,550	9,589	-17.00	-8,171	9,793	11,794	3,477	731	2,345
Share Based Compensation	-97.9%	182	8,846	8,423	6,065	4,996	5,727	5,754	3,894	3,620	3,663	3,992	3,330	3,181	3,126	2,918	2,921	2,769	2,558	2,579	2,641	1,836
Cashflow From Investing	-29.6%	22,402	31,840	10,172	9,933	-46,717	-101,849	-5,271	-2,539	-4,689	-3,273	-3,524	-2,159	-2,145	-2,049	-2,025	-2,185	-2,979	-2,568	-2,398	-2,233	-524
Cashflow From Financing	-94.8%	367	7,107	1,302	-1,361	202	4,994	2,207	894	-216	4,176	7,833	6,000	6,550	4,317	7,440	1,264	828	-111	-328	-240	-446

STAA Income Statement

2023-12-29

CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands

12 Months Ended

Dec. 29, 2023

Dec. 30, 2022

Dec. 31, 2021

Income Statement [Abstract]

Net sales

$ 322,415

$ 284,391

$ 230,472

Cost of sales

69,764

61,008

51,835

Gross profit

252,651

223,383

178,637

Selling, general and administrative expenses:

General and administrative

72,319

54,742

44,142

Selling and marketing

107,834

88,856

67,294

Research and development

44,401

35,983

33,862

Total selling, general and administrative expenses

224,554

179,581

145,298

Operating income

28,097

43,802

33,339

Other income (expense), net:

Interest income (expense), net

6,986

2,448

(38)

Loss on foreign currency transactions

^[1]

(1,909)

(1,707)

(2,964)

Royalty income

804

1,015

Other income (loss), net

448

205

(48)

Total other income (expenses), net

5,599

1,750

(2,035)

Income before income taxes

33,696

45,552

31,304

Provision for income taxes

12,349

5,887

3,793

Net income

$ 21,347

$ 39,665

$ 27,511

Net income per share:

Basic

$ 0.44

$ 0.83

$ 0.58

Diluted

$ 0.43

$ 0.80

$ 0.56

Weighted average shares outstanding:

Basic

48,523

47,987

47,210

Diluted

49,427

49,380

49,456

[1]	Shown as a separate line item on the Consolidated Statements of Income.

STAA Balance Sheet

2023-12-29

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 29, 2023	Dec. 30, 2022
Current assets:
Cash and cash equivalents	$ 183,038,000	$ 86,480,000
Investments available for sale	37,688,000	125,159,000
Accounts receivable trade, net	94,704,000	62,447,000
Inventories, net	35,130,000	24,161,000
Prepayments, deposits and other current assets	14,709,000	13,476,000
Total current assets	365,269,000	311,723,000
Investments available for sale	11,703,000	13,902,000
Property, plant and equipment, net	66,835,000	50,921,000
Finance lease right-of-use assets, net	183,000	342,000
Operating lease right-of-use assets, net	34,387,000	30,270,000
Intangible assets, net		173,000
Goodwill	1,786,000	1,786,000
Deferred income taxes	5,190,000	8,744,000
Other assets	3,339,000	957,000
Total assets	488,692,000	418,818,000
Current liabilities:
Accounts payable	13,557,000	11,576,000
Obligations under finance leases	165,000	169,000
Obligations under operating leases	4,202,000	3,524,000
Allowance for sales returns	6,174,000	5,706,000
Other current liabilities	40,938,000	30,741,000
Total current liabilities	65,036,000	51,716,000
Obligations under finance leases	42,000	210,000
Obligations under operating leases	31,425,000	27,136,000
Deferred income taxes	1,077,000	1,489,000
Asset retirement obligations	103,000	220,000
Pension liability	5,055,000	1,935,000
Total liabilities	102,738,000	82,706,000
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock, $0.01 par value; 60,000 shares authorized: 48,839 and 48,212 shares issued and outstanding at December 29, 2023 and December 30, 2022, respectively	488,000	482,000
Additional paid-in capital	436,947,000	404,189,000
Accumulated other comprehensive income (loss)	(4,113,000)	156,000
Accumulated deficit	(47,368,000)	(68,715,000)
Total stockholders’ equity	385,954,000	336,112,000
Total liabilities and stockholders’ equity	$ 488,692,000	$ 418,818,000

About STAAR Surgical Co

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

CEO	Mr. Thomas G. Frinzi
WEBSITE	staar.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	882

STAAR Surgical Co Frequently Asked Questions

What is the ticker symbol for STAAR Surgical Co? What does STAA stand for in stocks?

STAA is the stock ticker symbol of STAAR Surgical Co. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of STAAR Surgical Co (STAA)?

As of Tue Apr 23 2024, market cap of STAAR Surgical Co is 2.35 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of STAA stock?

You can check STAA's fair value in chart for subscribers.

What is the fair value of STAA stock?

You can check STAA's fair value in chart for subscribers. The fair value of STAAR Surgical Co is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of STAAR Surgical Co is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for STAA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is STAAR Surgical Co a good stock to buy?

The fair value guage provides a quick view whether STAA is over valued or under valued. Whether STAAR Surgical Co is cheap or expensive depends on the assumptions which impact STAAR Surgical Co's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STAA.

What is STAAR Surgical Co's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, STAA's PE ratio (Price to Earnings) is 110.31 and Price to Sales (PS) ratio is 7.3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STAA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on STAAR Surgical Co's stock?

In the past 10 years, STAAR Surgical Co has provided 0.097 (multiply by 100 for percentage) rate of return.